Russia plans first drug-development cashback awards by year-end

First project selection planned this year

Russia’s Ministry of Industry and Trade expects to conduct the first selection of innovative pharmaceutical projects eligible for reimbursement of final-stage clinical trial costs by the end of the year, Interfax reported on September 3. Industry and Trade Minister Anton Alikhanov said the proposed support instrument, described as “cashback for success,” is intended to cover part of the expenditure associated with Phase III trials.

The draft government resolution establishing the mechanism has already been submitted to the Russian government for approval, according to Alikhanov. The selection therefore depends on the final adoption of the regulatory framework. The minister did not identify a specific launch date, participating companies or candidate medicines.

Payments capped at 2.5 billion rubles

Under the proposed rules, a first-in-class medicine could receive compensation of up to 2.5 billion rubles. The payment would also be limited to no more than 50% of a project’s total costs. This means developers would remain responsible for at least half of the relevant expenditure even when receiving the maximum permitted level of state support.

The mechanism’s planned annual budget is 10 billion rubles, Alikhanov said. At the maximum reimbursement of 2.5 billion rubles per medicine, that budget would be equivalent to four maximum-size awards, although the actual number of supported projects could be higher if individual payments are smaller. Interfax did not report how the annual funding would be distributed among therapeutic areas or how competing applications would be ranked.

Eligibility would be restricted to projects that have already obtained Russian registration certificates for original medicines. Those certificates must have been issued within the three years preceding the selection, but not before 2025. The design therefore links reimbursement to products that have successfully reached registration rather than providing advance financing for medicines that may not complete development.

Therapeutic priorities will shape eligibility

Applicants would also have to work in therapeutic areas covered by the mechanism. Russia’s Ministry of Health has drawn up the relevant list of priority areas, according to Interfax. No individual therapeutic categories were specified in the source material, leaving the potential mix of eligible products and developers unclear until the rules and accompanying criteria are published.

For Russian pharmaceutical producers, the proposal could reduce part of the financial burden associated with the most advanced and expensive stage of clinical development. The 50% ceiling, however, preserves a substantial funding requirement for developers. The registration condition also makes commercial and regulatory execution central to obtaining reimbursement: support would follow a successful product launch process rather than replace the capital needed to reach it.

The government is separately considering assistance for Phase I and Phase II clinical trials of original medicines. Alikhanov said that support would be implemented through a different mechanism based at the autonomous nonprofit organization Center for Support of Engineering and Innovation. No budget, reimbursement limit or timetable for this early-stage instrument was disclosed. Together, the two initiatives indicate an effort to support different points in domestic drug development, but the Phase III cashback program remains subject to government approval before its first selection can proceed.